Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression

Gene

Volumn 497, Issue 2, 2012, Pages 301-306

  Yu, Hong ^a   Zhao, Gang ^b   Li, Hui ^b   Liu, Xiaojian ^c   Wang, Shijun ^b  

^a NANTONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Candesartan; Cardiac remodeling; MMP 9; Smad7; TGF 1

Indexed keywords

CANDESARTAN; COLLAGEN; FIBRONECTIN; GELATINASE B; NIFEDIPINE; PROTEIN; ROCK 1 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; DOWN REGULATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE WALL; HEART PROTECTION; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; CELLS, CULTURED; COLLAGEN; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; FIBRONECTINS; GENE KNOCKDOWN TECHNIQUES; HEART VENTRICLES; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; NIFEDIPINE; PRESSURE; RHO-ASSOCIATED KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; SMAD7 PROTEIN; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; VENTRICULAR REMODELING;

MUS;

EID: 84862814406     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.01.081     Document Type: Article

References (37)

1. Ago T., Yang Y., Zhai P., Sadoshima J. Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload. J. Cardiovasc. Transl. Res. 2010, 3:304-313.
2. Akashiba A., Ono H., Ono Y., Ishimitsu T., Matsuoka H. Valsartan improves L-NAME-exacerbated cardiac fibrosis with TGF-ss inhibition and apoptosis induction in spontaneously hypertensive rats. J. Cardiol. 2008, 52:239-246.
3. Alexander C.M., Werb Z. Targeted disruption of the tissue inhibitor of metalloproteinases gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro. J. Cell Biol. 1992, 118:727-739.
4. Boettner B., Van Aelst L. The role of Rho GTPases in disease development. Gene 2002, 286:155-174.
5. Cohn R.D., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 2007, 13:204-210.
6. Cuspidi C., Negri F., Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc. Health Risk Manag. 2008, 4:67-73.
7. Dobaczewski M., et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ. Res. 2010, 107:418-428.
8. El-Haddad M.A., et al. Role of irbesartan in prevention of post-coronary artery bypass graft atrial fibrillation. Am. J. Cardiovasc. Drugs 2011, 11:277-284.
9. Flanders K.C. Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol. 2004, 85:47-64.
10. Heckbert S.R., et al. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am. J. Hypertens. 2009, 22:538-544.
11. Huang P., Zhang Y., Jiang T., Zeng W., Zhang N. Aldose reductase is a potent regulator of TGF-beta1 induced expression of fibronectin in human mesangial cells. Mol. Biol. Rep. 2010, 37:3097-3103.
12. Huang X.R., et al. Smad3 mediates cardiac inflammation and fibrosis in angiotensin II-induced hypertensive cardiac remodeling. Hypertension 2010, 55:1165-1171.
13. Izumi N., et al. BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290:L120-L126.
14. Kantola A.K., Keski-Oja J., Koli K. Induction of human LTBP-3 promoter activity by TGF-beta1 is mediated by Smad3/4 and AP-1 binding elements. Gene 2005, 363:142-150.
15. Kawai M., et al. Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. Hypertens. Res. 2009, 32:604-610.
16. Leary A.C., MacDonald T.M. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology. Int. J. Clin. Pract. 1998, 52:475-481.
17. Lei B., et al. Effect of efonidipine on TGF-beta1-induced cardiac fibrosis through Smad2-dependent pathway in rat cardiac fibroblasts. J. Pharmacol. Sci. 2011, 117:98-105.
18. Li P., et al. Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ. Res. 2008, 102:185-192.
19. Li L., et al. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. Hypertens. Res. 2010, 33:1289-1297.
20. Liu C., Tazzeo T., Janssen L.J. Isoprostane-induced airway hyperresponsiveness is dependent on internal Ca2+ handling and Rho/ROCK signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 291:L1177-L1184.
21. Miura S., Karnik S.S., Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J. Renin Angiotensin Aldosterone Syst. 2011, 12:1-7.
22. Morizono K., et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat. Med. 2005, 11:346-352.
23. Ono A., et al. Glutathione redox regulates TGF-beta-induced fibrogenic effects through Smad3 activation. FEBS Lett. 2009, 583:357-362.
24. Poobalarahi F., Baicu C.F., Bradshaw A.D. Cardiac myofibroblasts differentiated in 3D culture exhibit distinct changes in collagen I production, processing, and matrix deposition. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2924-H2932.
25. Rikitake Y., et al. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation 2005, 112:2959-2965.
26. Sawicki G., Menon V., Jugdutt B.I. Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade. J. Card. Fail. 2004, 10:442-449.
27. Sebag I.A., et al. Quantitative assessment of regional myocardial function in mice by tissue Doppler imaging: comparison with hemodynamics and sonomicrometry. Circulation 2005, 111:2611-2616.
28. Seminario-Vidal L., et al. Thrombin promotes release of ATP from lung epithelial cells through coordinated activation of rho- and Ca2+-dependent signaling pathways. J. Biol. Chem. 2009, 284:20638-20648.
29. Silvestre J.S., et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999, 99:2694-2701.
30. Sukumaran V., et al. Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertens. Res. 2010, 33:695-702.
31. Tomita H., et al. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998, 32:273-279.
32. Tveit A., et al. Candesartan in the prevention of relapsing atrial fibrillation. Int. J. Cardiol. 2007, 120:85-91.
33. Wang S., Hirschberg R. Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J. Biol. Chem. 2004, 279:23200-23206.
34. Xiao H., et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc. Res. 2010, 87:504-513.
35. Yeh C.H., Chang C.K., Cheng M.F., Lin H.J., Cheng J.T. The antioxidative effect of bone morphogenetic protein-7 against high glucose-induced oxidative stress in mesangial cells. Biochem. Biophys. Res. Commun. 2009, 382:292-297.
36. Zeisberg E.M., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007, 13:952-961.
37. Zhang R.Y., Wang L.F., Zhang L., Meng X.N., Li S.J., Wang W.R. Effects of angiotensin converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats. Chin. Med. J. (Engl) 2006, 119:649-655.